Outlook Therapeutics (OTLK) Revenue (2015 - 2025)

Outlook Therapeutics (OTLK) reported Revenue of -$91787.0 for Q3 2025, down 106.1% quarter-over-quarter from $1.5 million in Q2 2025.

Outlook Therapeutics (OTLK) Revenue (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has 6 years of Revenue data on file, last reported at -$91787.0 in Q3 2025.

  • Revenue for Q3 2025 came in at -$91787.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $7.9 million (changed N/A YoY), and the FY2025 annual result was $1.4 million, changed N/A from the prior year.
  • Revenue eased to -$91787.0 in Q3 2025 per OTLK's latest filing, from $1.5 million in the prior quarter.
  • Over five years, Revenue peaked at $1.5 million in Q2 2025 and troughed at -$91787.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - 5.21 Mn
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 306.30 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 2.99 Bn
9 Abivax 94.37 Bn 94.37 Bn - -
10 Outlook Therapeutics 51.56 Mn 43.81 Mn -21,888.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 -91,787.00
Jun 30, 2025 1.51 Mn
Sep 30, 2019 5.85 Mn
Jun 30, 2019 583,848.00
Mar 31, 2019 641,140.00
Dec 31, 2018 1.07 Mn
Sep 30, 2018 771,890.00
Jun 30, 2018 771,890.00
Mar 31, 2018 771,890.00
Dec 31, 2017 771,890.00
Sep 30, 2017 2.90 Mn
Jun 30, 2017 303,140.00
Mar 31, 2017 303,140.00
Dec 31, 2016 303,140.00
Sep 30, 2016 494,894.00
Jun 30, 2016 494,894.00
Mar 31, 2016 994,894.00
Dec 31, 2015 994,894.00
Sep 30, 2015 494,894.00
Jun 30, 2015 1.29 Mn